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Abstract
Background: As second-line antiretroviral treatment (ART) becomes more accessible in resource-limited settings
(RLS), the need for more affordable monitoring tools such as point-of-care viral load assays and simplified
genotypic HIV drug resistance (HIVDR) tests increases substantially. The prohibitive expenses of genotypic HIVDR
assays could partly be addressed by focusing on a smaller region of the HIV reverse transcriptase gene (RT) that
encompasses the majority of HIVDR mutations for people on ART in RLS. In this study, an in silico analysis of
125,329 RT sequences was performed to investigate the effect of submitting short RT sequences (codon 41 to 238)
to the commonly used virco®TYPE and Stanford genotype interpretation tools.
Results: Pair-wise comparisons between full-length and short RT sequences were performed. Additionally, a non-
inferiority approach with a concordance limit of 95% and two-sided 95% confidence intervals was used to
demonstrate concordance between HIVDR calls based on full-length and short RT sequences.
The results of this analysis showed that HIVDR interpretations based on full-length versus short RT sequences, using
the Stanford algorithms, had concordance significantly above 95%. When using the virco®TYPE algorithm, similar
concordance was demonstrated (>95%), but some differences were observed for d4T, AZT and TDF, where predic-
tions were affected in more than 5% of the sequences. Most differences in interpretation, however, were due to
shifts from fully susceptible to reduced susceptibility (d4T) or from reduced response to minimal response (AZT,
TDF) or vice versa, as compared to the predicted full RT sequence. The virco®TYPE prediction uses many more
mutations outside the RT 41-238 amino acid domain, which significantly contribute to the HIVDR prediction for
these 3 antiretroviral agents.
Conclusions: This study illustrates the acceptability of using a shortened RT sequences (codon 41-238) to obtain
reliable genotype interpretations by virco®TYPE and Stanford algorithms. Implementation of this simplified protocol
could significantly reduce the cost of both resistance testing and ARV treatment monitoring in RLS.
Introduction
In most developed countries, HIV treatment monitoring
guidelines recommend regular viral load (VL) testing
and HIV drug resistance (HIVDR) testing in the case of
virologic failure and prior to treatment initiation [1,2].
In contrast, current clinical practice in resource-limited
settings (RLS) is predominantly based on clinical staging
and/or CD4 measurements [3]. However, the latest
WHO recommendations promote strategic introduction
of VL monitoring as well as greater access to CD4 test-
ing for treatment initiation [4]. In 2003 WHO and
UNAIDS initiated a public health approach to HIV
management by recommending standardized antiretro-
viral (ARV) treatment regimens in order to improve the
access to HIV treatment in RLS [5]. This approach has
been successful and the number of patients on treat-
ment in low- and middle-income countries has since
increased 10-fold to more than 4 million at the end of
2008 [6]. Despite these joint efforts, laboratory tools to
monitor patients on treatment are still lacking in many
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any medium, provided the original work is properly cited.parts of the world, due to the lack of infrastructure and
financial resources.
Several studies have shown that CD4 measurements
are inaccurate in predicting treatment failure [7-11],
which has resulted in the aforementioned WHO recom-
mendations. Therefore it is of utmost importance to
develop simple and affordable alternatives to the cur-
rently available VL and HIVDR tests that could be bet-
ter implemented in RLS. In the context of these
challenges a public-private consortium, aiming to bring
an affordable HIV monitoring algorithm to Africa
(ART-A: affordable resistance testing for Africa) was
established in 2008 with partners in South-Africa, Lux-
embourg, the Netherlands and Belgium [12]. The overall
aim of the ART-A project is to develop a more afford-
able HIV treatment monitoring system which can be
universally applied for both individual patient manage-
ment and public health purposes. In order to achieve
this, the project will look at the use of dried blood spots
and combine this with a cost-effective qualitative VL
testing and subtype-independent confirmatory HIVDR
genotyping with automated base-calling software to
reduce operator errors in identifying pure mutations
and mixture mutations. One strategy to reduce the costs
of HIVDR testing is to focus on a partial region of the
HIV-1 reverse transcriptase (RT) from codon 41 to 238.
This region covers all HIVDR mutations recognized by
the IAS [13]. This approach can be justified because
98% of the patients on treatment in RLS receive a first-
line drug regimen based on RT-inhibitors only [6].
Moreover, the mutations, commonly present in patients
failing a first-line drug regimen in RLS (M41L, D67N,
K65R, K70R, K103N, V106A/M, Y181C, M184V,
G190A, L210W, T215Y/F and K219Q/E) are all present
in the shorter RT sequence [8,14-17].
In this study, the potential effect on the prediction of
HIVDR by submitting a short RT sequence from amino
acid 41 to 238 to the virco®TYPE and Stanford resis-
tance interpretation algorithms was investigated through
an in silico analysis. It was not our intention to compare
the performance of virco®TYPE versus Stanford.
Materials and methods
Amplification of a short RT sequence useful in HIVDR
testing
As of today, HIV resistance testing is based on amplify-
ing and sequencing of the viral protease and reverse
transcription genes. This requires multiple rounds of
amplification and at least 6-8 sequencing reactions. For
RLS, we assumed that a cost-reduction could be imple-
mented by sequencing a short RT region. Amplification
of this short RT region (codon 41-238) is feasible using
a one-step single round amplification followed by a
simplified sequencing protocol. Proof of principle for
this cost-reduction approach is available [18].
Virco database analysis
A total of 125,323 full length RT sequences (codon
1-400) were retrieved from the Virco database. For all
these sequences, virco®TYPE interpretations were gener-
ated for the paired full-length RT (codon 1-400) and
short RT sequences (codon 41-238) on 8 FDA-approved
RT inhibitors commonly used in RLS [6] (lamivudine =
3TC, abacavir = ABC, zidovudine = AZT, stavudine =
d4T, didanosine = ddI, tenofovir = TDF, efavirenz = EFV
and nevirapine = NVP). A similar approach on non-B
subtypes (n = 17,131) was used for the Stanford HIVDR
interpretation algorithm.
virco®TYPE HIVDR interpretation tool
virco®TYPE calculates the phenotypic drug susceptibility
from a genotype, based on a linear regression model
[19]. The phenotypic drug susceptibility is expressed as
a fold change (FC) i.e. the ratio of inhibitory concentra-
tion 50% (IC50) of a patient-derived sample to the IC50
value of a reference strain (IIIB). virco®TYPE provides a
data-driven identification of mutations affecting FC and
the magnitude of their effect [19]. The calculated FC
per drug is interpreted using cut-off values. The virco®-
TYPE report uses clinical cut-offs (CCOs), where avail-
able [20]. Clinical cut-offs are used to facilitate the
interpretation of fold change and drug resistance. They
represent thresholds on the fold change continuum to
indicate loss in clinical drug activity due to resistance.
These cut-offs are determined based on observational
studies in treated patients. When the calculated FC falls
below the lower CCO, a maximal response (MA) to
treatment with that drug is predicted, whereas a mini-
mal response (MI) is expected if the FC falls above the
higher CCO value. A calculated FC that falls between
the lower and higher CCO predicts reduced response
(RE). When CCOs are not available for a particular drug
(EFV and NVP), biological cut-offs (BCOs) are used.
A biological cut-off is based on laboratory observations
of viruses derived from treatment naïve patients, and
gives an indication of the normal range of in vitro sus-
ceptibility of wild-type viruses. The virus is predicted to
be susceptible (S) or resista n t( R )t oas p e c i f i cd r u g
when the calculated FC is below or above the BCO,
respectively [21].
In this analysis virco®TYPE VPT4.3.00 was used, with
the clinical and biological cut-offs currently in use on
the virco®TYPE report [20]. The optimal sequence
length for virco®TYPE analysis is from codon 1 to 99 of
the protease region and from codon 1 to 400 of the RT
region. The minimal accepted sequence lengths are
Steegen et al. AIDS Research and Therapy 2010, 7:38
http://www.aidsrestherapy.com/content/7/1/38
Page 2 of 9from codon 10 to 95 and from codon 41 to 238 for pro-
tease and RT respectively. Any missing sequence length
should be filled with “***” or a reference strain sequence.
The virco®TYPE linear regression model then calculated
the resistance profile.
In this study the output from full RT sequences
(codon 1-400) were compared to the resistance predic-
tion of short RT sequences (codon 41-238), whereby the
protease gene and RT codon 1-40 were replaced by the
HXB2 reference strain sequence.
Stanford HIVDR interpretation tool
The Stanford HIV database interpretation algorithm is a
qualitative HIVDR interpretation tool that assigns a
mutation penalty score to each HIV mutation that is,
according to published studies, associated with drug
resistance [22]. The total score for a drug is derived by
adding up the scores of each mutation associated with
HIVDR to that drug. The interpretation tool subse-
quently reports one of the following levels of inferred
drug resistance: susceptible (S), potential low-level resis-
tant (pLR), low-level resistant (LR), intermediate resis-
tant (I) and high-level resistant (R) [22]. To simplify the
analysis, pLR was regarded as susceptible and LR was
interpreted as intermediate. Stanford algorithm version
5.0.0 was used in this analysis.
In contract to virco®TYPE, Stanford has no restrictions
on the sequence length input. For the Stanford analysis
the output from full RT sequences (codon 1-400) were
compared to the resistance prediction of short RT
sequences (codon 41-238).
Pair wise comparisons between HIVDR calls generated
from full RT and short RT
A pair wise comparison of the predicted HIVDR pro-
file (or resistance call) for each full-length and short
RT sequence pair was performed for both the virco®-
TYPE and Stanford HIVDR interpretation algorithms.
Changes in resistance calls between the full-length RT
and the short RT sequence were categorized in major
and minor call changes. Major HIVDR call changes are
defined as a switch from S to R and MI to MA, or vice
versa. Minor call changes include a switch from RE to
MA, RE to MI, I to R and I to S, or vice versa (Figure
1). A non-inferiority approach with a concordance
limit of 95% and two-sided 95% confidence intervals
was used to show if at least 95% of the HIVDR calls
based on the short RT sequence (codon 41-238) were
concordant with HIVDR calls based on the standard
RT sequence (codon 1-400).
Results
The dataset used for this analysis contained 125,329 RT
sequences. Only HIV subtypes with at least 500
sequences in the database were included for analysis.
The majority of sequences were derived from subtype B
viruses (n = 108,198), but other non-B subtypes were
also represented (n = 17,131). An assortment of ‘sensi-
tive’ (S or MA) and ‘resistant’ (RE, MI and R) profiles
towards different drugs was observed. The majority of
the subtype B sequences were susceptible to RT inhibi-
tors ranging from 52.6% (ABC) to 72.3% (d4T). Due to
the delayed introduction of ART in RLS, the proportion
of ‘sensitive’ profiles among the non-B subtypes is
higher with the exception of the rare subtypes F1 and
CRF12_BF. For the latter two subtypes, specific colla-
borations had been set up to obtain resistant viruses to
enrich the Virco database. A descriptive dataset distribu-
tion is depicted in Figure 2.
The HIVDR call changes between full RT and short
RT were analyzed per drug in two groups: group 1:
sequences that were attributed a ‘susceptible’ profile
(MA or S), based on virco®TYPE analysis of the full RT
sequence; and group 2: sequences that were attributed a
‘resistant’ profile (RE, MI or R), based on virco®TYPE
analysis of the full RT sequence.
Sequences interpreted by virco®TYPE
The virco®TYPE interpretation based on a full length RT
sequence (codon 1-400) was compared to the prediction
based on the shortened RT sequence (codon 41-238).
Figure 3a shows that in the ‘susceptible’ group (group
1) the minor call changes remained below 2%, when all
subtypes were pooled together. Subtype-specific analysis
demonstrated that at least 95% of HIVDR call-concor-
dance was observed for the majority of the drugs with
the exception of d4T. However, across the different
drugs, subtype F1 showed a higher proportion of minor
call changes, ranging from 3.2% for AZT to 8.0% for
d4T. Across subtypes, most minor changes were
observed for d4T, ranging from 1.3% for subtype B to
9.1% for subtype A1.
Less than 1.3% major call changes were detected when
all sequences from the ‘susceptible’ group were analyzed.
However, 2.6% of the subtype G sequences showed
major changes for EFV (Figure 3b).
The analyses for subtype F1 (3TC, ABC and TDF) and
subtype G (d4T) were inconclusive. This can be
e x p l a i n e db yt h es m a l l e rs a m p l es i z ef o rs u b t y p eF 1( N
= 745) and G (N = 560) as compared to the other sub-
types (N >1000).
In the other analyses, comparisons between the
HIVDR calls based on short and full length RT
sequences were concordant in at least 95% of the cases,
except for d4T in subtype A1, C, CRF01_AE and F1,
with concordance values of 90.87% (95% CI 90.25-
91.49%), 94.58% (95% CI 94.30-94.86%), 94.25% (95% CI
93.78-94.72%), 92.02% (95% CI 90.80-93.25%)
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minor call changes.
As expected, the proportion of call changes increased
in the group of ‘resistant’ samples (group 2), see Figure 4.
Overall, there were fewer than 12.6% minor call changes
but subtype-specific call changes of up to 19.6% were
detected for AZT on subtype G sequences (Figure 4a).
The highest number of major call changes in group 2
were seen among the subtype D samples for NVP (2.7%)
and EFV (6.3%), see Figure 4b for more details.
Due to small sample sizes the analyses were inconclu-
sive for the following groups: d4T (subtype A1, D and
F1), subtype G (ABC) and CRF01_AE (ABC). Non-infer-
iority analysis in the remaining groups revealed an infer-
ior HIVDR prediction when using short RT sequences
for ABC in subtype A1 sequences, d4T in CRF01_AE,
EFV in subtype D, AZT and TDF for all subtypes. As
previously observed, all discordances were caused by
minor call changes, with the exception of TDF on sub-
type A1 and B sequences, whereby just a small subset of
call changes was of the major type (0.22% and 0.02%,
respectively).
Sequences interpreted by Stanford
The Stanford HIVDR interpretation algorithm was
applied only to the non-B sequences (n = 17,131).
Neither minor nor major call changes were observed for
3TC, ABC, d4T ddI and TDF. The HIVDR calls for the
remaining drugs (AZT, EFV and NVP) changed only in
a few cases, with all changes being minor. For AZT, 7
sequences (0.04%) gave a different result when the short
RT sequence was submitted to Stanford. The HIVDR
level only changed in two sequences (0.01%) for EFV
and in 13 sequences (0.08%) for NVP.
Figure 1 Representation of the definition of minor and major changes in predicted HIVDR calls between full RT and short RT
sequences. *MA: maximal response; RE: reduced response; MI: minimal response; CCO1: lower clinical cut-off; CCO2: upper clinical cut-off;
S: susceptible; R: resistant; BCO: biological cut-off . **S: susceptible; pLR: potential low-level resistant; LR: low-level resistant; I: intermediate
resistant; R: high-level resistant.
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There is an increased need for affordable and robust
HIV monitoring tools in RLS, including point-of-care
VL assays and simplified HIVDR testing protocols.
Attempts are being made to simplify currently available
technologies in order to make them more accessible for
RLS. This study evaluated the use of reducing the
sequence length used to interpret HIVDR patterns.
The use of the shorter RT sequences in the virco®-
TYPE HIVDR interpretation tool was not inferior to the
full RT sequence for most drugs. An inferior HIVDR
interpretation in more than 5% of the cases was
detected only for d4T (subtype A1, C, F1 and
C R F 0 1 _ A E )i nt h eg r o u po f‘sensitive’ sequences. These
HIVDR interpretation changes were caused by minor
changes: from fully susceptible as predicted by the full
RT sequence to reduced susceptibility as predicted by
the short RT sequence. Moreover, recent WHO treat-
ment guidelines recommend to phase out the use of
d4T as preferred component of first-line treatment [4].
Therefore the clinical impact of HIVDR interpretation
for d4T will be limited. In the ‘resistant’ group, the
HIVDR prediction for AZT and TDF is of concern, as
more than 5% of the sequences yielded a different
HIVDR call for all subtypes when the short RT
sequence was submitted to virco®TYPE. However, all
call changes were minor (from ‘reduced response’ to
‘minimal response’, or vice versa), except for TDF for
subtype A1 and B samples (0.22% and 0.02% major call
changes, respectively). It is therefore unlikely that these
HIVDR interpretation changes will have a major clinical
impact. Because there is no clinical cut-off available for
the NNRTIs NVP and EFV, only major call changes
could be observed. The resistance call changes for those
two drugs were in most cases limited to less than 3%,
which is under our 5% cut-off. Moreover, the clinical
relevance for the resistance prediction of these drugs is
limited because they are not recommended in second
line regimens.
When the sequences were submitted to Stanford, call
changes were observed in less than 0.08% of the cases
f o rA Z T ,E F Va n dN V P ,s h o w i n gn oi n f e r i o r i t yo f
using the short sequence in any of the non-B subtypes
(B sequences were not analyzed). Observed HIVDR
interpretation differences between full RT and shor-
tened RT sequences in virco®TYPE can be explained by
the fact that the Virco algorithm includes resistance
weight factors for a substantial number of codon posi-
tions outside the RT codon 41-238 region which are
depicted in Table 1. The Stanford algorithm is based
on mutations that all lie within the region of RT
codon 41 to 238, except for 333D, 333E and 318F, (see
Table 1). The latter three mutations influence HIVDR
only towards AZT, EFV and NVP and were only pre-
sent in 2% of the non-B subtypes (405/17,131). One
could argue that part of the observed differences
Figure 2 Dataset, based on subtype and drug-specific full-length RT HIVDR profile by virco®TYPE.T h es u b t y p e sa r ea r r a n g e db y
decreasing prevalence of in the Virco database. MA: maximal response, S: susceptible.
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by the fact that the reference strains, used in Stanford
and virco®TYPE, are different (consensus B versus
HXB2 respectively). However, both reference strains
only differ from each other at four positions (codon
122, 214, 376 and 400). Moreover, in most cases, resis-
tance mutations at those four positions would be
picked up by both algorithms as they are different
from the reference amino acids found in either HXB2
or the consensus B sequence.
O v e r a l lt h i ss t u d ys h o w st h a tt h eu s eo fas h o r t e rR T
sequence genotype results in >95% concordance with
results obtained from full length RT sequences obtained
from two routinely used interpretation systems, virco®-
TYPE and Stanford. The results provide initial validation
that the simpler shorter genotype can be considered for
use in a new ARV-treatment monitoring system for use
in RLS.
Nevertheless, this study also has some limitations.
Firstly, despite a good representation of non-B subtypes
Figure 3 virco®TYPE call changes between full length and short RT HIVDR interpretations for sequences with a ‘susceptible’ profile,
based on full RT interpretation (group 1). A. Minor call changes. Minor changes are not possible for drugs with a BCO only as a shift can
only occur from susceptible to resistant (or vice versa), which is a major call change; therefore EFV and NVP are not depicted in this graph.
B. Major call changes MA: maximal response, S: susceptible.
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sequences in this database are subtype B, which is less
relevant for RLS. To accommodate this limitation,
further analysis on the effect of sequencing a short RT
fragment for HIVDR testing of RLS samples accessing
first-line regimens will be done in collaboration between
ART-A and the PASER (PharmAccess African Studies
to Evaluate Resistance) network [23]. Secondly, the
treatment data of the patients from which these
sequences were derived is missing and therefore we
could not make a clear differentiation between the resis-
tance interpretations in a treatment naïve group versus
a treatment exposed group. This issue will also be
addressed in the future study (mentioned above) as
treatment naïve and treatment failing patients will be
included. Thirdly, this simplified resistance assay only
focuses on assessing resistance in the RT gene, which is
relevant for RLS at the moment as most of the patients
receive a combination ARV regimen of RT inhibitors
only. However, when protease inhibitors will become
Figure 4 virco®TYPE call changes between full length and short RT HIVDR interpretations for sequences with a ‘resistant’ profile
based on full RT interpretation (group 2). A. Minor call changes. Minor changes are not possible for drugs with a BCO only as a shift can
only occur from susceptible to resistant (or vice versa), which is a major call change; therefore EFV and NVP are not depicted in this graph.
B. Major call changes RE: reduced response, MI: minimal response, R: resistant.
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include the protease gene as well.
Although this simplified HIVDR interpretation algo-
rithm still requires a lab infrastructure, skilled personnel
and investment in major equipment, it also has several
advantages. Firstly, amplification of the short RT region is
feasible using a one-step single round amplification proto-
col [18], which reduces the risk for contamination, mini-
mizes hands-on work and cuts down the reagent cost as
only one amplification primer set is needed. Secondly, the
sequencing is also simplified by reducing the number of
primers from 8 (in Virco’s in-house assay) to only 2.
Thirdly the analysis time of the obtained short RT
sequence is also reduced compared to the analysis of a full
RT sequence. The obtained short RT sequence can subse-
quently be submitted to either Stanford or virco®TYPE.
However, the biological starting material for this simplified
HIVDR algorithm is plasma, which might pose a problem
in RLS, as cold-chain transport and deep frozen storage is
still a challenge in many places. Therefore, the ART-A
team is currently investigating the feasibility of using dried
blood spots as a source material to overcome this issue.
In conclusion, this comparative analysis has shown that
HIVDR interpretation, based on shorter RT sequence, is
not inferior compared to the use of full RT sequences for
most of the commonly used HIV RT inhibitors in RLS.
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Table 1 Amino acid positions outside RT codon 41-238 contributing to the HIVDR interpretation algorithms. ROI:
region of interest
ROI ARV drugs Stanford virco®TYPE
RT codon 1-40 3TC none 7, 8, 13, 35, 36, 40 (n = 6)
ABC none 3, 13, 21, 33, 35, 39, 40 (n = 7)
AZT none none
d4T none 3, 13, 33, 35, 36, 40 (n = 6)
ddI none 3, 4, 33, 35, 36, 39, 40 (n = 7)
TDF none 4, 7, 13, 21, 33, 40 (n = 6)
EFV none 16, 20, 22, 27, 28, 31, 33, 34 (n = 8)
NVP none 21, 31, 35 (n = 3)
RT codon 239-400 3TC none 240, 248, 277, 313 (n = 4)
ABC none 334, 348 (n = 2)
AZT 333 (n = 1) 240, 242, 244, 245, 282, 296, 297, 313, 334, 335, 350, 357, 359, 360, 375, 377, 386, 395 (n = 18)
d4T none 334, 348, 357, 359 (n = 4)
ddI none 348, 359, 360, 395 (n = 4)
TDF none 242, 245, 249, 277, 297, 329, 334, 335, 353, 357, 359, 395 (n = 12)
EFV 318 (n = 1) 240, 241, 243, 244, 245, 250, 251, 257, 271, 272, 274, 282, 283, 286, 292, 297, 313, 317, 318,
329, 333, 334, 335, 338, 339, 348, 353, 356, 357, 358, 365, 366, 369, 370, 371, 375, 376, 377,
379, 381, 382, 385, 386, 390, 393, 394, 395, 400 (n = 48)
NVP 318 (n = 1) 244, 245, 248, 250, 272, 283, 286, 293, 297, 313, 317, 318, 329, 333, 334, 335, 338, 339, 348, 353,
356, 357, 358, 365, 366, 369, 370, 371, 374, 375, 376, 377, 379, 382, 385, 386, 390, 393, 394, 395,
399, 400 (n = 42)
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